公开(公告)号：WO2022125392A1

公开(公告)日：2022-06-16

申请号：PCT/US2021/061781

申请日：2021-12-03

申请人： CHIMERA BIOENGINEERING, INC. [US]/[US]

发明人： WANG, Benjamin ,  ZEINER, Gusti

IPC分类号： A61K35/17 ,  C12N5/00

摘要： Methods and compositions for reducing Notch inhibition of T-cell activation are disclosed. Also, disclosed are RDEs which can be used to optimize expression of transgenes, e.g., CARs, in a eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell. Such CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anti cancer therapies.

公开(公告)号：WO2019160815A1

公开(公告)日：2019-08-22

申请号：PCT/US2019/017503

申请日：2019-02-11

申请人： CHIMERA BIOENGINEERING, INC. ,  WANG, Benjamin ,  ZEINER, Gusti ,  MCNALLY, Krista

发明人： WANG, Benjamin ,  ZEINER, Gusti ,  MCNALLY, Krista

IPC分类号： A61K35/17 ,  C12N15/85

摘要： Control Devices are disclosed including RNA destabilizing elements (RDE), and RNA control devices, combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. RDEs can be combined with RNA control devices to make RDEs that include ligand mediated control. These smart RDEs and other RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell.

公开(公告)号：WO2018045177A1

公开(公告)日：2018-03-08

申请号：PCT/US2017/049628

申请日：2017-08-31

申请人： CHIMERA BIOENGINEERING, INC. ,  WANG, Benjamin ,  ZEINER, Gusti

发明人： WANG, Benjamin ,  ZEINER, Gusti

IPC分类号： A61K35/17 ,  A61K35/28 ,  A61K39/00 ,  A61K39/395 ,  C12N5/00

摘要： Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.

摘要翻译： 在真核细胞中公开了控制装置，包括RNA失稳元件（RDE），RNA控制装置和与嵌合抗原受体（CAR）或其他转基因组合的去稳定元件（DE）。 还公开了多顺反子载体用于在控制装置的控制下用CAR和转基因工程宿主真核细胞。 这些控制装置可用于优化真核细胞中CAR的表达，以便例如效应功能得到优化。 CARs和转基因有效载荷也可以被工程化为真核细胞，从而转基因有效载荷在CAR在真核细胞上被刺激后被表达和递送。

公开(公告)号：WO2017100176A1

公开(公告)日：2017-06-15

申请号：PCT/US2016/065116

申请日：2016-12-06

申请人： CHIMERA BIOENGINEERING, INC.

发明人： WANG, Benjamin ,  ZEINER, Gusti

IPC分类号： A61K39/00 ,  C07K14/705 ,  C07K16/28 ,  C12N5/00

CPC分类号： A61K35/17 ,  A61K35/28 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2035/124 ,  A61K2039/505 ,  C07K16/2866 ,  C07K16/2896 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/74 ,  A61K2300/00

摘要： In an aspect, the present invention relates generally to the field of treating disease with CAR devices, Smart CAR devices, DE CAR devices, and/or Smart-DE CAR devices. The present invention also relates generally to the genetic modification of cytotoxic T-lymphocytes to reduce target cell killing by apoptosis and/or increase production of lytic proteins at desired times. In an aspect, the invention relates to the use of these genetically modified T-lymphocytes and/or natural killer cells with CAR devices, Smart CAR devices, DE CAR devices, and/or Smart-DE CAR devices to enhance the immune response against a disease.

摘要翻译： 一方面，本发明一般涉及用CAR装置，Smart CAR装置，DE CAR装置和/或Smart-DE CAR装置治疗疾病的领域。 本发明还一般涉及细胞毒性T淋巴细胞的遗传修饰以减少细胞凋亡对靶细胞的杀伤和/或在所需时间增加裂解蛋白的产生。 一方面，本发明涉及将这些基因修饰的T淋巴细胞和/或天然杀伤细胞与CAR装置，Smart CAR装置，DE CAR装置和/或Smart-DE CAR装置一起用于增强对抗 疾病

公开(公告)号：WO2022260968A1

公开(公告)日：2022-12-15

申请号：PCT/US2022/032254

申请日：2022-06-03

申请人： CHIMERA BIOENGINEERING, INC.

发明人： WANG, Benjamin ,  ZEINER, Gusti ,  ROCHE, Daniel

IPC分类号： A61K35/17 ,  A61K47/50 ,  C07K16/28 ,  C12N15/67

摘要： Methods and compositions for controlling transgene expression in Natural Killer Cells are disclosed. Also, disclosed are RDEs which can be used to optimize expression of transgenes in NK cells following activation pf the NK cell through a receptor, e.g., CARs or T-cell receptors. CARs and transgene payloads can also be engineered into NK cells so that the transgene payload is expressed and delivered at desired times from the NK cell. Such CAR NK cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies.

公开(公告)号：WO2022086875A1

公开(公告)日：2022-04-28

申请号：PCT/US2021/055469

申请日：2021-10-18

申请人： CHIMERA BIOENGINEERING, INC.

发明人： WANG, Benjamin ,  ZEINER, Gusti

IPC分类号： A61K35/17 ,  C07K14/715 ,  C07K14/705 ,  A61P35/00

摘要： Control Devices are disclosed including RNA destabilizing elements (RDE) combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. These RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell. Such CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anti cancer therapies.

公开(公告)号：WO2021034653A1

公开(公告)日：2021-02-25

申请号：PCT/US2020/046349

申请日：2020-08-14

申请人： CHIMERA BIOENGINEERING, INC.

发明人： WANG, Benjamin ,  ZEINER, Gusti ,  DYLLA, Scott

IPC分类号： A61K35/17 ,  A61K47/50 ,  C07K16/28 ,  C12N15/67 ,  C12N5/10 ,  A61K2039/5156 ,  A61K39/001112 ,  A61K39/001124 ,  A61K39/001129 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70578 ,  C07K14/7155 ,  C07K14/7156 ,  C07K2319/03

摘要： Control Devices are disclosed including RNA destabilizing elements (RDE) combined with transgenes, including Chimeric Antigen Receptors (CARs) in eukaryotic cells. These RDEs can be used to optimize expression of transgenes, e.g., CARs, in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered at desired times from the eukaryotic cell. Such CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies.

公开(公告)号：WO2017201019A1

公开(公告)日：2017-11-23

申请号：PCT/US2017/032861

申请日：2017-05-16

申请人： CHIMERA BIOENGINEERING, INC.

发明人： WANG, Benjamin ,  ZEINER, Gusti

IPC分类号： A61K35/17 ,  A61K39/395 ,  A61K48/00 ,  C07H21/04 ,  C07H21/02 ,  C07K16/28 ,  C07K14/705 ,  C12N5/0783 ,  C12N5/078

摘要： The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel CARs that utilize the novel antigen binding domains as an extracellular element. The present invention also relates to use of the novel antigen binding domains as therapeutic agents.

摘要翻译： 本发明总体上涉及制备抗感染性疾病的新型抗原结合结构域的领域。 本发明还涉及利用新型抗原结合结构域作为胞外元件的新型CAR。 本发明还涉及新型抗原结合结构域作为治疗剂的用途。

公开(公告)号：WO2016149254A1

公开(公告)日：2016-09-22

申请号：PCT/US2016/022442

申请日：2016-03-15

申请人： CHIMERA BIOENGINEERING, INC.

发明人： WANG, Benjamin ,  ZEINER, Gusti

IPC分类号： A61K35/17 ,  C12N5/0783

CPC分类号： C07K16/2887 ,  A61K48/0066 ,  A61K2039/505 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2510/00

摘要： The present invention relates generally to the field of RNA Control Devices and/or destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) in eukaryotic cells. The present invention also relates to split CARs (Side-CARs) in eukaryotic cells. More specifically, the present invention relates to DEs, RNA Control Devices, and/or side-CARs combined with Chimeric Antigen Receptors to make small molecule actuatable CAR polypeptides. The present invention also relates to DE-CARs, Smart CARs (Smart = small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs for use in the treatment of disease.

摘要翻译： 本发明一般涉及在真核细胞中与嵌合抗原受体（CAR）组合的RNA控制装置和/或去稳定化元件（DE）的领域。 本发明还涉及真核细胞中的分裂CAR（Side-CAR）。 更具体地，本发明涉及与嵌合抗原受体结合以制备小分子致动性CAR多肽的DE，RNA控制装置和/或侧CAR。 本发明还涉及用于治疗疾病的DE-CAR，Smart CAR（Smart =小分子致动RNA触发器），Smart-DE-CAR和/或Side-CAR。